Mutations in the KRAS gene are implicated in approximately 30% of all cancers, including lung, colorectal, and pancreatic cancers. These mutations often lead to the continuous activation of KRAS protein, resulting in uncontrolled cell proliferation and survival. As such, targeting KRAS mutations holds promise for developing effective cancer therapies.
